Risteys ·

OMOP concept ID	Test name	Measurement unit (harmonized unit)	N people	N records	Missing measurement value	Harmonized value distribution
40771922	pt-krea-cl	— (—)	144	194	100.00%	Distribution not available
40771922	pt-krea-cl	ml/s/1.73_m2 (ml/s/173m2)	127	143	0.00%
40771922	pt-krea-cl	ml/s/1.73m2 (ml/s/173m2)	91	130	0.00%
40771922	pt-krea-cl	ml/min (ml/s/173m2)	24	28	0.00%

LabWAS

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

Dialysis, with operation codes

142

60.69

255.24

1.4

1.5

0.75

1.76

ml/s/173m2

7.23

120

Nephropathy related operations

137

54.08

240.97

1.4

1.5

0.75

1.70

ml/s/173m2

7.11

118

Renal failure

161

17.23

176.72

1.4

1.3

0.62

1.74

ml/s/173m2

14.88

119

All chronic kidney diseases

177

15.24

175.69

1.4

1.3

0.70

1.83

ml/s/173m2

17.88

125

Chronic kidney disease

126

20.34

161.26

1.4

1.3

0.62

1.70

ml/s/173m2

11.92

Transplanted organ and tissue status

35.18

147.61

1.2

1.4

1.38

1.51

ml/s/173m2

0.23

Acute renal failure

23.69

131.29

1.5

1.1

0.47

1.60

ml/s/173m2

7.34

L04AD Calcineurin inhibitors

26.19

130.12

1.2

1.5

1.38

1.48

ml/s/173m2

0.20

Renal tubulo-interstitial diseases

174

158

8.09

111.95

1.4

1.3

0.78

2.41

ml/s/173m2

2.26

128

All kidney diseases

171

156

7.35

97.70

1.4

1.3

0.91

2.45

ml/s/173m2

1.99

126

ILD medications: immunosuppressive drugs

128

161

7.22

83.23

1.3

1.32

1.76

ml/s/173m2

0.36

L04AA Selective immunosuppressants

12.34

76.92

1.3

1.23

1.30

ml/s/173m2

0.13

Implicit bacterial Sepsis

9.98

76.43

1.4

1.3

0.66

1.47

ml/s/173m2

6.36

Implicit bacterial Sepsis, including avohilmo

9.19

73.34

1.4

1.2

0.65

1.43

ml/s/173m2

6.72

Bacterial Sepsis

100

8.82

73.13

1.4

1.2

0.68

1.52

ml/s/173m2

8.01

Implicit Sepsis

131

144

6.71

72.86

1.4

1.2

0.73

2.20

ml/s/173m2

1.58

100

Other septicaemia, including avohilmo

9.64

72.34

1.4

1.12

1.43

ml/s/173m2

1.18

Other septicaemia

9.69

71.93

1.4

1.12

1.45

ml/s/173m2

1.23

Explicit Sepsis

8.85

71.56

1.4

1.3

1.10

1.60

ml/s/173m2

2.93

Other bacterial diseases

157

184

5.66

71.12

1.3

1.4

1.07

1.92

ml/s/173m2

1.10

117

111

Heart failure, not strict

132

6.73

70.43

1.4

1.3

0.86

1.50

ml/s/173m2

5.51

Explicit Sepsis, including avohilmo

100

8.54

70.27

1.4

1.2

1.10

1.58

ml/s/173m2

2.73

Implicit Sepsis, including avohilmo

133

148

6.43

70.22

1.4

1.2

0.74

2.21

ml/s/173m2

1.65

Septicaemia

8.76

69.52

1.4

1.10

1.41

ml/s/173m2

1.29

Cirrhosis, broad definition used in the article https://doi.org/10.1101/594523

14.37

62.99

1.1

1.2

1.51

0.91

ml/s/173m2

1.99

Dental caries

10.51

62.86

1.4

1.3

1.22

1.09

ml/s/173m2

0.29

Condition for Implicit Sepsis (Organ dysfunction codes)

129

152

5.89

62.00

1.4

1.2

0.72

2.23

ml/s/173m2

1.76

Diseases of liver

8.30

61.93

1.2

1.3

1.45

1.16

ml/s/173m2

0.97

Bacterial infection, other or unspecified

111

7.24

60.07

1.3

0.93

1.48

ml/s/173m2

2.69

Bacterial infection, other or unspecified, including avohilmo

100

123

6.67

58.17

1.3

0.94

1.45

ml/s/173m2

2.78

Other bacterial diseases, including avohilmo

143

188

4.75

52.91

1.3

1.4

1.14

1.96

ml/s/173m2

1.03

106

111

Glomerular diseases

10.24

51.92

1.5

1.4

0.58

1.18

ml/s/173m2

3.97

Condition for Implicit Sepsis (Organ dysfunction codes), including avohilmo

123

161

5.16

51.40

1.4

1.3

1.32

1.66

ml/s/173m2

0.24

Caries of dentine

10.02

51.12

1.3

1.00

1.07

ml/s/173m2

0.13

Glomerular disorders in diseases classified elsewhere

12.88

47.71

1.4

1.3

0.57

1.11

ml/s/173m2

2.58

Implicit viral Sepsis, including avohilmo

9.20

47.24

1.3

1.2

0.87

1.56

ml/s/173m2

3.68

ILD medications: prednisolone, methylprednisolone, prednisone

134

165

4.52

44.67

1.2

1.4

1.20

1.71

ml/s/173m2

0.46

Implicit viral Sepsis

10.72

43.47

1.4

1.2

0.87

1.59

ml/s/173m2

2.96

Viral Sepsis

10.72

43.47

1.4

1.2

0.87

1.59

ml/s/173m2

2.96

Persons with potential health hazards related to family and personal history and certain conditions influencing health status

131

195

4.25

42.94

1.2

1.4

1.32

1.78

ml/s/173m2

0.45

102

109

Persons encountering health services for specific procedures and health care

132

188

4.15

40.91

1.3

0.89

2.22

ml/s/173m2

2.27

113

ILD medications

133

172

4.17

39.96

1.2

1.4

1.22

1.73

ml/s/173m2

0.48

103

Fever of other and unknown origin

144

5.18

39.95

1.3

1.23

1.81

ml/s/173m2

0.44

First line medication for Crohn's disease

126

167

4.06

36.70

1.2

1.4

1.26

1.81

ml/s/173m2

0.51

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

123

237

3.50

32.11

1.3

1.10

1.67

ml/s/173m2

0.89

149

Alcoholic liver disease

11.93

31.63

1.1

1.3

1.15

1.01

ml/s/173m2

0.25

Anaemias

12.84

30.15

1.3

1.1

1.14

6.51

ml/s/173m2

0.56

Infections, IBD-co-morbidities

12.99

29.61

1.3

1.4

1.18

1.50

ml/s/173m2

—

Other diseases of liver

8.32

26.09

1.1

1.2

1.36

1.20

ml/s/173m2

0.27

Aplastic and other anaemias

130

4.44

25.08

1.3

0.90

1.10

ml/s/173m2

0.65

Gout, strict definition

6.75

25.01

1.3

0.63

0.92

ml/s/173m2

0.69

Gout, FINNGEN

5.51

24.60

1.2

1.4

0.64

1.13

ml/s/173m2

1.79

Bleeding

210

3.31

24.21

1.3

1.17

1.14

ml/s/173m2

0.08

144

Diabetic nephropathy, excluding more controls

7.57

23.96

1.3

0.48

1.32

ml/s/173m2

1.85

Other disorders of kidney and ureter

7.84

23.38

1.2

1.3

0.63

1.16

ml/s/173m2

2.05

Certain infectious and parasitic diseases

108

3.94

23.36

1.2

1.4

1.04

2.50

ml/s/173m2

0.95

Gout

5.46

23.14

1.2

1.4

0.64

1.06

ml/s/173m2

1.48

Diabetic nephropathy

6.55

22.97

1.3

0.48

0.98

ml/s/173m2

2.67

Acute tubulo-interstitial nephritis

123

4.19

22.04

1.2

1.3

0.91

2.65

ml/s/173m2

1.54

Tramadol

145

3.53

21.72

1.3

1.32

1.68

ml/s/173m2

0.26

Gout, unspecified

5.82

20.05

1.3

1.4

0.43

1.01

ml/s/173m2

3.07

Examination and observation for other reasons

4.36

19.92

1.1

1.3

1.29

1.31

ml/s/173m2

0.02

GASTRO-related operations

4.39

19.69

1.3

1.5

1.16

3.08

ml/s/173m2

0.69

Any gastric operation

4.39

19.69

1.3

1.5

1.16

3.08

ml/s/173m2

0.69

Heart failure,strict

4.51

19.64

1.3

0.53

1.38

ml/s/173m2

7.49

Gout, idiopatic and unspecified

5.01

19.45

1.2

1.3

0.68

1.02

ml/s/173m2

0.94

Neoplasms

121

3.47

19.05

1.4

1.3

1.50

1.33

ml/s/173m2

0.47

Oxycodone

103

4.24

18.83

1.5

1.3

0.89

1.02

ml/s/173m2

0.32

Insulin, combination of fast acting with intermediate-acting or long-acting

209

3.21

18.73

1.2

1.3

0.91

1.61

ml/s/173m2

1.08

137

Insulin medication

189

3.25

18.63

1.2

1.3

0.91

1.67

ml/s/173m2

1.10

126

Unspecified kidney failure

16.21

18.29

1.8

1.1

0.30

1.52

ml/s/173m2

6.77

Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder

21.90

18.17

1.2

1.4

1.70

0.71

ml/s/173m2

—

Other anaemias

127

3.91

18.11

1.3

1.05

ml/s/173m2

0.00

Ascites

15.38

17.94

1.1

1.2

0.99

0.98

ml/s/173m2

0.01

Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder, including Hilmo

16.62

17.84

1.2

1.6

1.70

0.71

ml/s/173m2

2.62

Malignant neoplasm

184

2.93

17.63

1.4

1.3

1.59

1.57

ml/s/173m2

0.02

115

Other and unspecified anaemias

126

3.88

17.60

1.3

1.04

ml/s/173m2

0.00

Malignant neoplasm, including Hilmo

183

2.93

17.59

1.4

1.3

1.58

1.57

ml/s/173m2

0.01

116

Any death

147

3.33

17.44

1.4

0.93

1.13

ml/s/173m2

0.69

100

Malignant neoplasm, wide definition

185

2.90

17.26

1.4

1.3

1.59

1.57

ml/s/173m2

0.02

116

Any event in cancer register

193

2.85

17.13

1.4

1.61

1.55

ml/s/173m2

0.05

118

Malignant neoplasm of liver and intrahepatic bile ducts, including Hilmo

22.05

16.86

1.1

1.4

1.69

0.61

ml/s/173m2

—

160

3.03

16.85

1.3

0.96

1.81

ml/s/173m2

0.88

COPD/asthma/ILD related pneumonia or pneumonia derived septicaemia

160

3.03

16.85

1.3

0.96

1.81

ml/s/173m2

0.88

Heart failure and antihypertensive medication

8.36

16.83

1.3

1.4

0.53

1.33

ml/s/173m2

3.97

Pneumonias (Asthma/COPD co-morbidities)

100

246

2.66

16.65

1.3

0.92

1.78

ml/s/173m2

1.83

156

Oral corticosteroids

100

218

2.69

16.52

1.3

1.4

1.08

1.64

ml/s/173m2

0.77

135

Pneumonia, organism unspecified

238

2.71

16.48

1.3

1.4

0.85

1.77

ml/s/173m2

1.94

152

Insulin, fast-acting

129

3.80

16.44

1.3

0.96

1.29

ml/s/173m2

1.16

Malignant neoplasm

183

2.85

16.30

1.4

1.3

1.56

1.58

ml/s/173m2

0.01

114

Complications of surgical and medical care, not elsewhere classified

244

2.65

16.23

1.4

1.3

1.04

1.57

ml/s/173m2

0.79

149

Inflammatory bowel disease treatment related agents

107

230

2.58

16.09

1.3

1.4

1.15

1.66

ml/s/173m2

0.73

144

All pneumoniae

101

253

2.59

16.07

1.3

1.4

0.94

1.75

ml/s/173m2

1.74

161

Diarrhoea and gastroenteritis of presumed infectious origin

230

2.87

15.51

1.3

1.07

1.71

ml/s/173m2

1.03

146

Erysipelas

121

3.64

15.43

1.2

1.3

0.79

1.47

ml/s/173m2

3.54

Hypertension

117

3.28

15.42

1.2

1.3

0.95

2.03

ml/s/173m2

1.01

Hypertension, essential

106

3.41

15.41

1.3

1.10

2.05

ml/s/173m2

0.73

Pneumonia (excl. viral and due to other infectious organisms not elsewhere classified)

257

2.54

15.09

1.3

1.4

0.88

1.75

ml/s/173m2

2.01

164

Polyneuropathies and other disorders of the peripheral nervous system

4.67

14.90

1.3

1.4

1.21

0.89

ml/s/173m2

0.79

Other medical care

3.90

14.88

1.2

1.3

1.42

1.66

ml/s/173m2

0.67

Hypertensive diseases

120

3.20

14.87

1.2

1.3

0.95

2.04

ml/s/173m2

1.07

Insulin, fast-acting or short human

139

3.53

14.79

1.3

0.96

1.27

ml/s/173m2

1.04

100

Type 2 diabetes, wide definition

165

2.91

14.78

1.2

1.4

0.96

1.15

ml/s/173m2

0.47

107

Glomerulonephritis

6.60

14.46

1.4

0.70

1.04

ml/s/173m2

0.92

Intestinal infectious diseases

272

2.52

14.33

1.3

1.4

1.08

1.62

ml/s/173m2

1.00

170

Influenza and pneumonia

245

2.47

13.99

1.3

1.4

1.00

1.77

ml/s/173m2

1.47

154

Liquid cancers, including Hilmo

3.93

13.95

1.2

1.4

1.60

0.90

ml/s/173m2

2.86

Hypertensive diseases (excluding secondary)

3.88

13.91

1.3

1.00

2.56

ml/s/173m2

0.91

Liquid cancers

4.36

13.91

1.1

1.4

1.65

0.85

ml/s/173m2

3.37

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified (FINNGEN)

4.47

13.82

1.5

1.2

1.38

2.70

ml/s/173m2

0.51

Erysipelas, including avohilmo

152

3.02

13.56

1.2

1.3

0.83

1.97

ml/s/173m2

1.23

Medical observation and evaluation for suspected diseases and conditions

3.56

13.55

1.3

0.98

1.31

ml/s/173m2

1.26

Diseases of arteries, arterioles and capillaries (FINNGEN)

6.64

13.52

1.2

1.3

0.82

1.36

ml/s/173m2

1.63

Other gastritis (incl. Duodenitis)

4.77

13.51

1.5

1.2

1.02

1.05

ml/s/173m2

0.03

Hypertensive heart and/or renal disease

6.13

13.47

1.4

0.59

1.09

ml/s/173m2

1.35

General symptoms and signs

169

2.61

13.16

1.3

1.18

1.77

ml/s/173m2

0.56

Other diseases of the digestive system

108

3.71

13.03

1.3

1.28

0.97

ml/s/173m2

0.73

GI-bleeding

105

3.72

12.76

1.3

1.28

0.94

ml/s/173m2

0.83

Polyarthropathies

164

2.74

12.44

1.3

1.4

0.70

1.77

ml/s/173m2

1.52

112

Disorders of parathyroid gland

5.05

11.98

1.1

1.2

0.90

0.83

ml/s/173m2

0.12

Insulin, intermediate and long-acting

194

2.84

11.98

1.2

1.3

0.82

1.62

ml/s/173m2

1.23

130

Solid cancers, including Hilmo

184

2.53

11.92

1.4

1.3

1.57

1.58

ml/s/173m2

0.01

115

Diseases of the digestive system

170

2.98

11.78

1.3

1.4

1.30

1.14

ml/s/173m2

0.36

114

Genitourinary diseases

3.35

11.72

1.3

1.4

1.00

1.91

ml/s/173m2

6.08

Other special examinations and investigations of persons without complaint or reported diagnosis

3.34

11.72

1.3

0.90

1.31

ml/s/173m2

1.87

General examination and investigation of persons without complaint and reported diagnosis

3.35

11.69

1.3

1.27

1.31

ml/s/173m2

0.05

Other disorders of skin and subcutaneous tissue

227

2.57

11.63

1.4

1.3

1.15

1.48

ml/s/173m2

0.38

148

Solid cancers

181

2.53

11.59

1.4

1.3

1.54

1.59

ml/s/173m2

0.03

113

Gastroduodenal ulcer

4.07

11.50

1.2

1.38

0.95

ml/s/173m2

0.63

Disorders of gallbladder, biliary tract and pancreas

233

2.35

11.45

1.3

1.4

1.24

1.45

ml/s/173m2

0.24

147

Heart failure, strict

134

2.91

11.32

1.3

0.51

1.09

ml/s/173m2

5.01

Primary_lymphoid and hematopoietic malignant neoplasms

3.91

11.25

1.1

1.3

1.64

0.86

ml/s/173m2

3.08

Dipeptidyl peptidase 4 (DPP-4) inhibitors

151

2.86

11.17

1.3

0.94

1.04

ml/s/173m2

0.26

Osteoporosis

4.52

11.13

1.4

1.2

1.20

0.90

ml/s/173m2

0.70

Other viral diseases

116

3.36

10.98

1.3

1.24

1.98

ml/s/173m2

0.65

Complications of medical and surgical care

241

2.50

10.88

1.4

1.3

1.02

1.52

ml/s/173m2

0.69

148

Intestinal infectious diseases, including avohilmo, including avohilmo

100

254

2.19

10.81

1.2

1.4

1.09

1.61

ml/s/173m2

0.88

159

Certain infectious and parasitic diseases, including avohilmo

3.14

10.71

1.3

1.4

1.14

1.66

ml/s/173m2

1.75

Diarrhoea and gastroenteritis of presumed infectious origin, including avohilmo

253

2.26

10.69

1.3

1.4

1.09

1.61

ml/s/173m2

0.87

158

Malignant neoplasm of digestive organs

3.34

10.67

1.2

1.4

1.39

0.93

ml/s/173m2

1.40

Other diseases of blood and blood-forming organs, wide

4.13

10.58

1.3

1.4

1.44

1.18

ml/s/173m2

0.57

Haemorrhage from respiratory passages

104

3.32

10.51

1.2

1.3

1.22

1.13

ml/s/173m2

0.19

Malignant neoplasm of digestive organs, including Hilmo

102

3.17

10.48

1.2

1.4

1.41

1.04

ml/s/173m2

0.87

Any reimbursement code in KELA

3.89

10.47

1.5

1.2

1.18

3.23

ml/s/173m2

0.61

Complications of procedures, not elsewhere classified

233

2.42

10.39

1.4

1.3

0.88

1.54

ml/s/173m2

1.06

141

Alcohol use disorder, Swedish definition

186

2.69

10.38

1.4

1.3

0.95

1.14

ml/s/173m2

0.66

124

All-cause Heart Failure

134

2.80

10.30

1.3

0.52

1.09

ml/s/173m2

4.77

Coagulation defects, purpura and other haemorrhagic conditions

4.27

10.28

1.1

1.3

1.49

1.11

ml/s/173m2

0.70

Malaise and fatigue

126

2.94

10.06

1.6

1.3

0.92

1.93

ml/s/173m2

0.82

202

2.54

9.89

1.4

1.3

1.00

1.56

ml/s/173m2

0.73

132

Oedema, not elsewhere classified

3.51

9.66

1.3

0.89

2.04

ml/s/173m2

0.61

Infections of the skin and subcutaneous tissue

235

2.47

9.59

1.4

1.3

1.26

1.62

ml/s/173m2

0.45

154

Other diseases of biliary tract

8.37

9.54

1.3

1.2

1.62

1.17

ml/s/173m2

0.94

Osteopathies and chondropathies

192

2.57

9.39

1.3

1.13

1.17

ml/s/173m2

0.08

127

Hyperparathyroidism

4.73

9.37

1.1

1.2

0.71

0.86

ml/s/173m2

0.32

198

2.53

9.35

1.4

1.3

0.98

1.16

ml/s/173m2

0.60

129

Certain disorders involving the immune mechanism

4.04

9.22

1.4

1.24

1.01

ml/s/173m2

0.40

Cellulitis

3.81

9.20

1.4

1.3

0.92

0.99

ml/s/173m2

0.09

Other disorders of fluid, electrolyte and acid-base balance

3.48

9.14

1.6

1.2

0.77

1.14

ml/s/173m2

1.06

Nausea and vomiting

3.53

9.11

1.6

1.5

0.93

1.31

ml/s/173m2

1.07

Autoimmune diseases excluding thyroid diseases

222

2.15

9.08

1.3

1.13

1.66

ml/s/173m2

0.78

147

Congenital malformations of the urinary system, including avohilmo

7.05

9.01

1.4

1.3

0.81

1.28

ml/s/173m2

1.04

Autoimmune diseases excluding thyroid diseases, strict definition

213

2.17

9.00

1.3

1.14

1.69

ml/s/173m2

0.78

141

Second line medication for Crohn's disease

229

2.44

8.95

1.3

1.41

1.56

ml/s/173m2

0.17

157

Follow-up examination after treatment for conditions other than malignant neoplasms

3.43

8.88

1.2

1.3

0.88

1.41

ml/s/173m2

1.55

COPD/asthma/ILD related infections

160

2.32

8.88

1.2

1.3

1.11

1.81

ml/s/173m2

0.67

COPD/asthma related infections

160

2.32

8.88

1.2

1.3

1.11

1.81

ml/s/173m2

0.67

Hypertensive Heart Disease

5.06

8.78

1.4

0.53

1.13

ml/s/173m2

1.90

Acute upper respiratory infections of multiple and unspecified sites

208

2.31

8.76

1.4

1.3

1.08

1.63

ml/s/173m2

0.69

128

Persons encountering health services in other circumstances, wide

230

2.08

8.73

1.3

1.39

1.54

ml/s/173m2

0.15

151

Other and unspecified polyneuropathies, also in other diseases

4.12

8.70

1.4

1.3

0.91

0.98

ml/s/173m2

0.10

Gastrointestinal diseases

3.16

8.61

1.4

1.3

1.20

2.78

ml/s/173m2

0.53

Gastric ulcer

4.38

8.60

1.2

1.42

0.99

ml/s/173m2

0.41

Opioids

150

2.34

8.44

1.3

1.04

1.69

ml/s/173m2

0.55

Other reaction to severe stress, and adjustment disorders

116

3.02

8.38

1.2

1.3

1.38

2.02

ml/s/173m2

0.38

Bipolar affective disorders

4.45

8.35

1.7

1.1

1.19

2.97

ml/s/173m2

0.54

Congenital malformations of the urinary system

7.08

8.24

1.4

0.70

1.27

ml/s/173m2

1.41

Persons encountering health services for other counselling and medical advice, not elsewhere classified

230

2.06

8.23

1.3

1.30

1.54

ml/s/173m2

0.28

151

L04AX Other immunosuppressants

222

2.39

8.09

1.4

1.3

1.35

1.55

ml/s/173m2

0.21

152

Vertebral, anorectal, cardiavascular, thracheoesophagial, renal and limb anomaly, including avohilmo

3.41

8.08

1.4

1.3

0.82

1.56

ml/s/173m2

3.04

Other diseases of pleura

135

2.71

8.02

1.3

0.79

1.02

ml/s/173m2

0.82

Provisional assignment of new diseases of uncertain etiology

197

2.47

8.02

1.3

0.99

1.55

ml/s/173m2

0.72

132

Codes for special purposes

197

2.47

8.01

1.3

0.99

1.55

ml/s/173m2

0.72

132

Persons encountering health services in other circumstances

135

2.79

7.90

1.4

1.3

0.98

1.82

ml/s/173m2

0.76

Heart failure and coronary heart disease

2.93

7.90

1.2

1.4

0.51

1.04

ml/s/173m2

3.15

Purpura and other haemorrhagic conditions

4.62

7.86

1.1

1.4

1.60

0.94

ml/s/173m2

1.17

Abnormal findings on diagnostic imaging and in function studies, without diagnosis

226

2.27

7.85

1.2

1.3

1.11

1.45

ml/s/173m2

0.40

142

Congenital malformations, deformations and chromosomal abnormalities, including avohilmo

221

2.31

7.80

1.3

1.06

1.75

ml/s/173m2

1.16

149

Other heart diseases, wide

206

2.14

7.79

1.3

1.25

1.80

ml/s/173m2

0.72

140

Diseases of oesophagus, stomach and duodenum

240

2.04

7.78

1.3

1.26

1.50

ml/s/173m2

0.28

153

Hernia of abdominal wall, postoperative

6.03

7.77

1.1

1.3

1.09

1.47

ml/s/173m2

0.71

Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

4.62

7.75

1.3

1.4

1.13

1.43

ml/s/173m2

0.53

Surgical and other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

216

2.36

7.73

1.3

1.03

1.55

ml/s/173m2

0.62

134

Diverticular disease of intestine

169

2.28

7.73

1.2

1.3

1.15

1.10

ml/s/173m2

0.12

101

Cardiovascular diseases (excluding rheumatic etc)

2.66

7.62

1.2

1.3

1.16

2.44

ml/s/173m2

1.03

Persons with potential health hazards related to socioeconomic and psychosocial circumstances

3.19

7.61

1.6

1.2

1.82

2.16

ml/s/173m2

0.17

Other heart diseases

2.85

7.60

1.4

1.3

1.16

2.50

ml/s/173m2

1.01

Covid-19 confirmed case

134

2.76

7.59

1.2

1.3

0.88

1.06

ml/s/173m2

0.47

DVT of lower extremities and pulmonary embolism

134

2.75

7.54

1.4

1.3

0.65

1.02

ml/s/173m2

1.72

Congenital malformations, deformations and chromosomal abnormalities

206

2.35

7.45

1.2

1.3

1.03

1.78

ml/s/173m2

1.24

141

Vertebral, anorectal, cardiavascular, thracheoesophagial, renal and limb anomaly

3.32

7.25

1.3

0.73

1.57

ml/s/173m2

3.95

Missing teeth due to accident, extraction or parodontitis

207

2.29

7.23

1.2

1.3

1.37

0.97

ml/s/173m2

1.00

136

Metabolic disorders

215

2.06

7.20

1.4

1.3

1.11

1.75

ml/s/173m2

0.89

138

Other viral diseases, including avohilmo

148

2.61

7.20

1.3

1.24

1.92

ml/s/173m2

0.71

107

Disorders of other endocrine glands

166

2.49

7.05

1.5

1.2

1.18

1.80

ml/s/173m2

0.68

116

Type 2 diabetes

197

2.09

7.04

1.2

1.3

1.16

1.60

ml/s/173m2

0.50

130

Exposure to unspecified factor

287

1.94

6.99

1.3

1.33

1.49

ml/s/173m2

0.19

186

Excluding asthma or asthma-COPD overlap

123

2.32

6.97

1.2

1.4

1.05

1.26

ml/s/173m2

0.74

Venous thromboembolism

175

2.42

6.93

1.5

1.2

0.73

1.10

ml/s/173m2

1.40

112

Other bacterial intestinal infections

3.96

6.88

1.1

1.4

1.30

1.15

ml/s/173m2

0.20

Cutaneous abscess, furuncle and carbuncle

3.11

6.84

1.5

1.3

1.11

1.21

ml/s/173m2

0.14

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified

237

2.00

6.82

1.3

1.29

1.42

ml/s/173m2

0.14

153

Symptoms and signs involving the digestive system and abdomen

183

2.03

6.58

1.2

1.4

1.20

1.17

ml/s/173m2

0.09

113

Obesity due to excess calories

175

2.40

6.57

1.4

1.3

0.71

1.75

ml/s/173m2

1.63

120

Hypothyroidism and >3 levothyroxin purchases

5.02

6.55

1.6

1.1

1.36

6.51

ml/s/173m2

0.53

Hypothyroidism, levothyroxine purchases

5.02

6.55

1.6

1.1

1.36

6.51

ml/s/173m2

0.53

Polyuria

3.17

6.55

1.6

1.2

1.58

0.86

ml/s/173m2

1.07

Hypothyroidism (congenital or acquired)

5.01

6.54

1.6

1.1

1.36

6.51

ml/s/173m2

0.53

Bacterial intestinal infections, IBD co-morbidities

3.81

6.52

1.1

1.3

1.30

1.01

ml/s/173m2

0.46

Fitting and adjustment of other devices

3.30

6.51

1.3

0.92

1.42

ml/s/173m2

1.46

Diseases of arteries, arterioles and capillaries

176

2.21

6.44

1.3

0.73

1.08

ml/s/173m2

1.69

115

Symptoms and signs involving the urinary system

227

2.06

6.38

1.4

1.3

2.27

1.15

ml/s/173m2

0.49

144

Non-ischemic cardiomyopathy

3.00

6.35

1.5

1.4

0.55

1.05

ml/s/173m2

2.22

Other nutritional deficiencies

232

2.13

6.26

1.4

1.3

0.97

1.57

ml/s/173m2

0.85

156

Other pulmonary diagnosis

123

2.24

6.26

1.2

1.4

1.05

1.26

ml/s/173m2

0.74

Benign neoplasm of colon, rectum, anus and anal canal

203

2.17

6.22

1.2

1.3

1.13

0.99

ml/s/173m2

0.36

127

Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

205

2.24

6.16

1.3

0.90

1.54

ml/s/173m2

0.77

129

Sequelae with surgical and medical care as external cause

3.51

6.15

1.3

1.2

0.74

1.03

ml/s/173m2

0.77

Obesity

224

2.14

6.08

1.4

1.3

0.98

1.59

ml/s/173m2

0.81

150

Type 2 diabetes, definitions combined, including avohilmo

189

2.02

6.07

1.3

1.31

1.62

ml/s/173m2

0.30

126

Obesity and other hyperalimentation

224

2.14

6.06

1.4

1.3

0.98

1.59

ml/s/173m2

0.81

150

COPD differential diagnosis

125

2.21

6.05

1.2

1.4

1.04

1.24

ml/s/173m2

0.64

ILD differential diagnosis

125

2.21

6.05

1.2

1.4

1.04

1.24

ml/s/173m2

0.64

Other retinal disorders

174

2.18

5.98

1.3

1.4

0.87

1.15

ml/s/173m2

1.01

109

Abnormal findings on examination of other body fluids, substances and tissues, without diagnosis

144

2.32

5.95

1.4

1.3

2.78

1.18

ml/s/173m2

0.44

Unspecified haematuria

127

2.44

5.91

1.3

3.26

1.09

ml/s/173m2

0.54

Obesity, other/unspecified

112

2.68

5.90

1.4

1.3

1.17

1.95

ml/s/173m2

0.49

Diseases of the skin and subcutaneous tissue

181

1.97

5.89

1.3

1.15

1.66

ml/s/173m2

0.58

119

Diabetes, insuline treatment (Kela reimbursement), excluding more controls

218

1.93

5.84

1.2

1.3

1.05

1.64

ml/s/173m2

0.94

150

Complications of internal orthopaedic prosthetic devices, implants and grafts

3.60

5.75

1.2

0.72

1.27

ml/s/173m2

1.53

Cardiovascular diseases

2.47

5.71

1.2

1.3

1.23

2.59

ml/s/173m2

0.92

218

1.86

5.68

1.4

1.3

1.16

1.53

ml/s/173m2

0.42

132

Non-rheumatic valve diseases

104

2.47

5.60

1.3

1.4

0.86

1.28

ml/s/173m2

1.16

Diabetes, insulin treatment (Kela reimbursement)

248

1.85

5.58

1.2

1.4

1.04

1.59

ml/s/173m2

0.95

164

Seborrhoeic keratosis

3.19

5.58

1.4

1.2

1.59

0.97

ml/s/173m2

0.73

Acute pancreatitis

3.28

5.57

1.2

1.4

1.41

0.99

ml/s/173m2

0.80

Bronchitis

259

1.83

5.56

1.4

1.3

1.08

1.49

ml/s/173m2

0.62

164

Thrombocytopenia, unspecified

6.52

5.55

1.1

1.3

1.90

0.76

ml/s/173m2

—

Abdominal and pelvic pain

183

1.92

5.46

1.2

1.4

1.30

1.17

ml/s/173m2

0.42

113

Other disorders of urethra and urinary system

174

2.08

5.44

1.4

1.14

1.69

ml/s/173m2

0.49

104

Diabetes mellitus

226

1.87

5.42

1.2

1.4

1.18

1.66

ml/s/173m2

0.66

152

Pulmonary heart disease, diseases of pulmonary circulation

100

2.70

5.41

1.3

0.65

0.92

ml/s/173m2

0.83

Pain in limb

224

1.90

5.38

1.3

1.21

1.68

ml/s/173m2

0.63

145

Other cataract

116

2.37

5.35

1.2

1.4

0.70

1.18

ml/s/173m2

2.14

Type 2 diabetes, definitions combined

192

1.94

5.34

1.3

1.32

1.61

ml/s/173m2

0.28

128

Excessive, frequent and irregular menstruation

3.11

5.34

1.2

1.3

0.90

1.41

ml/s/173m2

1.45

Abnormalities of heart beat

103

2.64

5.33

1.4

1.56

1.87

ml/s/173m2

0.12

Acute upper respiratory infections

241

1.84

5.32

1.4

1.3

1.12

1.49

ml/s/173m2

0.48

147

Other soft tissue disorders, not elsewhere classified

228

1.85

5.31

1.3

1.19

1.69

ml/s/173m2

0.73

147

Acute pancreatitis (for exclusion)

3.18

5.30

1.2

1.3

1.41

0.98

ml/s/173m2

0.86

All influenza

2.78

5.28

1.0

1.3

1.31

1.45

ml/s/173m2

0.25

Benign neoplasm: Colon

187

2.16

5.27

1.2

1.3

1.13

1.01

ml/s/173m2

0.27

114

Diabetes medication

244

1.82

5.25

1.3

1.4

1.15

1.58

ml/s/173m2

0.60

162

Reimbursement for rheumatic diseases

219

2.09

5.24

1.4

1.3

1.16

1.53

ml/s/173m2

0.45

149

Antihypertensive medication - note that there are other indications

2.45

5.20

1.3

0.95

2.59

ml/s/173m2

1.25

Type 2 diabetes, strict (exclude DM1)

194

1.92

5.19

1.3

1.4

1.32

1.61

ml/s/173m2

0.28

128

Care involving use of rehabilitation procedures

168

2.19

5.19

1.3

1.22

2.28

ml/s/173m2

1.28

101

Valvular heart disease excluding rheumatic fever

109

2.36

5.11

1.3

1.4

0.86

1.33

ml/s/173m2

1.37

Diabetes, varying definitions

228

1.83

5.08

1.2

1.4

1.17

1.65

ml/s/173m2

0.67

155

Other bacterial intestinal infections, including avohilmo

3.08

5.05

1.1

1.3

1.30

1.25

ml/s/173m2

0.06

Constipation

265

1.81

5.05

1.3

1.4

1.32

1.51

ml/s/173m2

0.23

173

Anxiety disorders, excluding more controls

199

1.93

5.04

1.4

1.3

1.24

1.61

ml/s/173m2

0.36

126

DVT of lower extremities

3.40

5.02

1.5

1.2

0.59

0.99

ml/s/173m2

1.28

Symptoms and signs involving the skin and subcutaneous tissue

270

1.92

4.97

1.2

1.4

1.23

1.48

ml/s/173m2

0.32

164

ILD, hospital admissions 1, main diag only

3.67

4.92

1.3

0.82

0.76

ml/s/173m2

—

Headache

152

2.13

4.85

1.4

1.3

1.36

1.83

ml/s/173m2

0.36

Iron deficiency anaemia

140

2.31

4.82

1.5

1.3

0.74

1.69

ml/s/173m2

0.91

Insulin, fast-acting (human)

4.84

4.80

1.1

1.2

0.66

1.27

ml/s/173m2

—

Diseases of the respiratory system

2.22

4.75

1.2

1.4

1.05

1.13

ml/s/173m2

0.17

Hydronephrosis

5.72

4.74

1.4

1.0

0.52

1.71

ml/s/173m2

—

Abnormal findings on diagnostic imaging of lung

160

2.19

4.74

1.3

0.80

1.06

ml/s/173m2

0.93

100

Sleep apnoea

238

1.80

4.68

1.4

1.3

1.06

1.47

ml/s/173m2

0.59

157

Vitreous haemorrhage

4.68

4.67

1.4

1.2

0.37

1.16

ml/s/173m2

—

Sulfasalazine

2.90

4.59

1.6

1.3

0.77

2.35

ml/s/173m2

0.73

Agranulocytosis

4.53

4.55

1.4

1.50

1.03

ml/s/173m2

—

Neurological diseases, wide definition

2.96

4.51

1.3

1.32

1.68

ml/s/173m2

0.69

Persistent mood disorders

3.27

4.46

1.6

1.1

0.67

1.27

ml/s/173m2

1.95

Disorders of continuity of bone

5.23

4.45

1.1

0.84

1.02

ml/s/173m2

—

Disorders of choroid and retina

225

1.84

4.43

1.3

0.83

1.13

ml/s/173m2

1.44

143

Abnormal findings in secretions and smears from cervix uteri vagina vulva

2.37

4.40

1.4

1.3

3.95

1.35

ml/s/173m2

0.45

Persons encountering health services for examination and investigation

2.29

4.39

1.2

1.3

0.89

1.31

ml/s/173m2

1.73

Injuries to the abdomen, lower back, lumbar spine and pelvis

147

2.21

4.39

1.3

1.04

1.09

ml/s/173m2

0.09

Candidiasis, including avohilmo

2.62

4.38

1.1

1.3

1.45

2.09

ml/s/173m2

0.32

Menorrhagia

3.00

4.36

1.3

0.99

1.30

ml/s/173m2

0.66

ILD, hospital admissions

3.34

4.32

1.3

1.4

0.82

0.88

ml/s/173m2

—

Interstitial lung disease

3.34

4.32

1.3

1.4

0.82

0.88

ml/s/173m2

—

Interstitial lung disease endpoints

3.34

4.32

1.3

1.4

0.82

0.88

ml/s/173m2

—

Benzodiazepine use

268

1.74

4.31

1.4

1.3

1.14

1.42

ml/s/173m2

0.36

167

Other (not insulin) diabetes medications

214

1.78

4.29

1.3

1.23

1.52

ml/s/173m2

0.30

139

Ulcer of lower limb, not elsewhere classified

3.95

4.29

1.3

1.11

1.13

ml/s/173m2

—

Asthma, unspecified (mode), excluding more controls

101

2.27

4.22

1.3

1.4

0.93

1.35

ml/s/173m2

1.21

Atrial fibrillation and flutter

2.93

4.20

1.8

1.3

1.34

1.50

ml/s/173m2

0.19

Persons with potential health hazards related to communicable diseases

138

2.23

4.20

1.4

1.3

1.26

1.90

ml/s/173m2

0.63

104

Pulmonary embolism

2.56

4.20

1.4

1.3

0.69

0.96

ml/s/173m2

0.72

Other interstitial pulmonary diseases

3.27

4.18

1.3

0.82

0.88

ml/s/173m2

—

Pleural effusion

3.27

4.18

1.5

1.2

0.79

0.94

ml/s/173m2

—

Asthma, excluding more controls

107

2.06

4.17

1.3

1.4

1.03

1.35

ml/s/173m2

1.10

Neurotic, stress-related and somatoform disorders

246

1.76

4.17

1.4

1.3

1.30

1.55

ml/s/173m2

0.29

164

Calcific aortic valvular stenosis, diagnosis (helper)

2.62

4.17

1.3

0.76

0.80

ml/s/173m2

0.06

Operations 2 for CAVS

2.62

4.17

1.3

0.76

0.80

ml/s/173m2

0.06

Calcific aortic valvular stenosis, including rheumatic fever

2.61

4.16

1.3

0.76

0.80

ml/s/173m2

0.06

Cerebrovascular diseases (FINNGEN)

2.96

4.15

1.1

1.3

1.45

1.49

ml/s/173m2

0.05

Mycoses

2.53

4.12

1.1

1.3

1.46

1.08

ml/s/173m2

0.73

Other respiratory disorders and diseases

2.80

4.11

1.2

1.3

0.76

1.05

ml/s/173m2

0.63

Other diseases of the respiratory system

2.80

4.11

1.2

1.3

0.76

1.05

ml/s/173m2

0.63

Acute sinusitis

157

2.08

4.09

1.3

1.2

1.22

1.88

ml/s/173m2

0.60

Anxiety disorders

247

1.75

4.06

1.4

1.3

1.30

1.55

ml/s/173m2

0.29

165

Dyspnoea

266

1.74

4.06

1.3

0.85

1.57

ml/s/173m2

1.47

168

Pulmonary heart disease

2.50

4.03

1.4

1.3

0.69

0.93

ml/s/173m2

0.64

Calcific aortic valvular stenosis

2.55

3.99

1.3

0.76

0.85

ml/s/173m2

0.13

Calcific aortic valvular stenosis, operated

2.55

3.99

1.3

0.76

0.85

ml/s/173m2

0.13

Heart failure and bmi 25plus

2.25

3.96

1.5

1.3

0.54

0.94

ml/s/173m2

1.63

Zoster [herpes zoster]

3.02

3.95

1.3

1.2

1.45

0.95

ml/s/173m2

0.91

Pure hypercholesterolaemia

165

1.89

3.95

1.3

1.2

0.66

1.22

ml/s/173m2

2.90

103

Nutritional anaemias

168

2.04

3.93

1.4

1.3

0.72

1.55

ml/s/173m2

0.96

106

Fracture of lumbar spine and pelvis

2.81

3.93

1.2

0.79

0.99

ml/s/173m2

0.35

Amputation

4.45

3.93

1.6

1.3

0.16

0.92

ml/s/173m2

—

Convulsions, not elsewhere classified

2.90

3.91

1.4

1.2

0.97

1.24

ml/s/173m2

0.52

Irregular menses

2.27

3.90

1.4

1.2

1.16

2.31

ml/s/173m2

0.61

Chronic gastritis

2.63

3.88

1.1

1.2

1.08

0.99

ml/s/173m2

0.14

Endocrine, nutritional and metabolic diseases

126

1.92

3.88

1.4

1.2

1.10

2.13

ml/s/173m2

1.02

Fracture of foot, except ankle

2.56

3.87

1.4

1.3

0.68

1.29

ml/s/173m2

2.13

Autoimmune diseases

224

1.68

3.87

1.4

1.3

1.09

1.65

ml/s/173m2

0.86

148

Type 1 diabetes, wide definition, subgroup 1

2.77

3.84

1.4

0.49

1.42

ml/s/173m2

4.20

Diaphragmatic hernia

113

2.30

3.83

1.3

1.30

0.98

ml/s/173m2

0.44

Other and unspecified disorders of skin and subcutaneous tissue

6.02

3.81

1.9

1.3

0.35

0.89

ml/s/173m2

—

Umbilical hernia

2.42

3.79

1.1

1.3

1.00

1.04

ml/s/173m2

0.08

Other diseases of intestines

245

1.66

3.77

1.4

1.3

1.19

1.65

ml/s/173m2

0.69

154

Acute suppurative otitis media

2.54

3.76

1.7

1.2

1.46

2.41

ml/s/173m2

0.50

Used for control exclusion in common control thyroid runs

209

1.69

3.76

1.4

1.3

1.12

1.69

ml/s/173m2

0.83

139

Abnormalities of breathing

188

1.76

3.74

1.2

1.4

0.99

1.75

ml/s/173m2

1.04

124

Other specified/unspecified arthritis

2.45

3.70

1.4

0.76

2.14

ml/s/173m2

0.98

Sequelae of external causes of morbidity and mortality

2.53

3.62

1.3

1.2

0.74

1.07

ml/s/173m2

0.97

Disorders of lipoprotein metabolism and other lipidaemias

176

1.80

3.61

1.3

1.2

0.76

1.26

ml/s/173m2

3.10

109

Mood disorders, excluding more controls

209

1.71

3.60

1.5

1.3

1.22

1.53

ml/s/173m2

0.32

132

Autoimmune diseases related-to ILD

278

1.71

3.58

1.3

1.4

1.45

1.41

ml/s/173m2

0.03

179

Ulcerative colitis

2.50

3.53

1.4

1.3

1.59

1.15

ml/s/173m2

1.08

Presence of other devices

2.81

3.51

1.2

1.4

0.62

0.85

ml/s/173m2

0.61

Cardiac arrhythmias

115

2.01

3.50

1.4

1.39

2.14

ml/s/173m2

0.52

Viral infections characterized by skin and mucous membrane lesions, including avohilmo

302

1.65

3.48

1.3

2.23

1.22

ml/s/173m2

0.51

187

Percutaneous Coronary Intervention

201

1.72

3.47

1.3

1.4

0.88

1.30

ml/s/173m2

2.37

133

Any mental disorder, or suicide (or attempt), or psychic disorders complicating pregnancy, partum or puerperum or nerve system disorders, excluding more controls

2.61

3.46

1.5

1.2

1.03

2.34

ml/s/173m2

0.63

Coronary revascularization (ANGIO or CABG)

201

1.72

3.46

1.3

1.4

0.88

1.30

ml/s/173m2

2.37

133

Diseases of the eye and adnexa

160

1.75

3.45

1.4

1.3

1.10

1.88

ml/s/173m2

0.90

108

Peripheral artery disease

113

2.10

3.42

1.3

0.47

0.95

ml/s/173m2

2.53

Hernia

247

1.67

3.42

1.2

1.4

1.23

1.48

ml/s/173m2

0.27

157

Polycystic ovarian syndrome, consortium definition

111

1.96

3.40

1.4

1.3

1.07

2.06

ml/s/173m2

0.61

Presence of cardiac and vascular implants and grafts

100

2.13

3.40

1.3

1.5

0.40

0.97

ml/s/173m2

2.98

Sulfonylureas

2.30

3.40

1.4

1.3

0.67

0.84

ml/s/173m2

0.42

Benign neoplasm: Rectum

2.83

3.35

1.3

0.80

0.92

ml/s/173m2

—

Urinary track infection

2.05

3.30

1.2

1.5

0.99

2.70

ml/s/173m2

0.89

Asthma

122

1.86

3.30

1.3

1.4

1.00

1.25

ml/s/173m2

0.81

Use of pramipexole

2.62

3.29

1.3

1.2

0.95

1.00

ml/s/173m2

—

Other diseases of urinary system

235

1.62

3.29

1.3

1.08

1.64

ml/s/173m2

0.88

150

Neurological diseases

163

1.73

3.29

1.3

1.4

1.34

1.91

ml/s/173m2

0.54

102

Hyperlipidaemia, other/unspecified

109

2.14

3.23

1.3

1.2

0.66

1.13

ml/s/173m2

1.97

Type 1 diabetes

2.33

3.22

1.1

1.4

0.63

1.37

ml/s/173m2

3.20

Paralytic ileus and intestinal obstruction

2.38

3.21

1.3

0.91

1.11

ml/s/173m2

0.39

Other/unspecified seropositive rheumatoid arthritis (ICD-10)

2.58

3.20

1.5

1.2

0.55

1.12

ml/s/173m2

1.68

Asthma, unspecified (mode)

116

1.99

3.15

1.3

1.4

0.93

1.24

ml/s/173m2

0.83

Pain (limb, back, neck, head abdominally)

135

1.78

3.15

1.2

1.4

1.01

1.28

ml/s/173m2

1.07

Other respiratory diseases principally affecting the interstitium

2.73

3.15

1.3

0.82

0.92

ml/s/173m2

—

Atrial fibrillation and flutter with reimbursement

3.04

3.13

1.2

1.4

0.88

1.39

ml/s/173m2

—

Hernia of abdominal wall

165

1.94

3.12

1.1

1.3

0.97

1.16

ml/s/173m2

0.51

110

Zoster [herpes zoster], including avohilmo

180

1.88

3.09

1.3

1.35

1.47

ml/s/173m2

0.09

113

Intestinal stricture

105

2.19

3.08

1.3

1.09

0.95

ml/s/173m2

0.25

Codeine

148

1.75

3.05

1.2

1.3

1.11

1.69

ml/s/173m2

0.47

Type of accident

2.22

3.05

1.4

1.3

1.15

1.14

ml/s/173m2

0.01

Emergency coronary revascularization (for ACS)

217

1.64

3.05

1.3

1.4

0.88

1.25

ml/s/173m2

1.96

139

Diabetic retinopathy, strict definition

2.46

3.03

1.4

1.3

0.47

1.04

ml/s/173m2

2.47

Erosion of teeth , including avohilmo

2.30

3.00

1.3

4.87

1.22

ml/s/173m2

0.51

Cholelithiasis, broad definition with cholecystitis

211

1.67

2.99

1.3

1.33

1.47

ml/s/173m2

0.13

131

Atherosclerosis, excluding cerebral and coronary sclerosis

103

2.06

2.97

1.4

0.43

0.92

ml/s/173m2

2.65

Cholelithiasis

207

1.68

2.96

1.3

1.4

1.34

1.48

ml/s/173m2

0.13

128

Other/unspecified seropositive rheumatoid arthritis

2.47

2.95

1.5

1.2

0.55

1.10

ml/s/173m2

1.60

Other symptoms and signs involving the digestive system and abdomen

3.25

2.92

1.3

1.2

1.91

1.05

ml/s/173m2

—

Cystitis

198

1.65

2.92

1.2

1.4

1.01

1.71

ml/s/173m2

0.92

124

Disorders of vitreous body and globe

194

1.80

2.89

1.2

1.3

1.05

1.01

ml/s/173m2

0.05

123

Sleep apnoea, including avohilmo

245

1.58

2.86

1.4

1.3

1.01

1.46

ml/s/173m2

0.67

158

Type 1 diabetes, wide definition

2.34

2.80

1.4

0.49

1.43

ml/s/173m2

4.34

Mood [affective] disorders

267

1.56

2.79

1.5

1.3

1.23

1.48

ml/s/173m2

0.30

167

Mood disorders

267

1.56

2.77

1.5

1.3

1.23

1.48

ml/s/173m2

0.30

167

Supplementary factors related to causes of morbidity and mortality classified elsewhere

110

2.09

2.77

1.4

1.3

1.15

1.17

ml/s/173m2

0.03

Hard cardiovascular diseases

209

1.61

2.76

1.2

1.4

0.89

1.33

ml/s/173m2

2.55

134

Seropositive rheumatoid arthritis

2.38

2.76

1.5

1.2

0.55

1.16

ml/s/173m2

1.85

Unspecified mental disorder

124

2.02

2.74

1.6

1.2

1.07

1.75

ml/s/173m2

0.58

Other arrhythmias

160

1.77

2.72

1.3

1.30

1.76

ml/s/173m2

0.38

107

Seropositive rheumatoid arthritis, wide

2.36

2.72

1.5

1.2

0.55

1.13

ml/s/173m2

1.73

Other neurological diseases

225

1.65

2.72

1.3

1.09

1.45

ml/s/173m2

0.42

144

Benign neoplasm: Rectum, anus and anal canal

2.50

2.69

1.3

0.80

0.86

ml/s/173m2

—

Other diseases of hard tissues of teeth

1.90

2.69

1.2

1.5

0.96

0.99

ml/s/173m2

0.05

Secondary malignant neoplasm of other and unspecified sites, including Hilmo

2.42

2.68

1.5

1.4

1.70

0.80

ml/s/173m2

—

Systemic connective tissue disorders

105

2.10

2.67

1.6

1.2

0.95

1.02

ml/s/173m2

0.10

Sequelae of cerebrovascular disease

106

2.02

2.67

1.3

1.4

0.57

0.80

ml/s/173m2

0.77

Exposure to other specified factors

299

1.58

2.64

1.4

1.3

0.97

1.59

ml/s/173m2

1.29

195

Abnormal findings on examination of blood, without diagnosis

178

1.78

2.63

1.5

1.3

0.96

1.08

ml/s/173m2

0.30

120

Fall on same level

271

1.49

2.63

1.2

1.4

1.19

1.60

ml/s/173m2

0.63

180

Suppurative and unspecified otitis media

105

2.02

2.62

1.6

1.2

1.35

2.06

ml/s/173m2

0.47

Other arthritis (FG)

106

2.08

2.62

1.4

1.2

0.76

2.13

ml/s/173m2

1.07

Presence of other functional implants

123

1.84

2.61

1.2

1.5

0.55

1.04

ml/s/173m2

3.05

Seborrhoeic dermatitis

3.34

2.60

1.6

1.4

2.52

1.03

ml/s/173m2

—

Pain in throat and chest

181

1.63

2.59

1.3

1.4

1.40

1.72

ml/s/173m2

0.28

117

Major coronary heart disease event

211

1.59

2.59

1.3

1.4

0.80

1.27

ml/s/173m2

3.03

136

Diseases of the musculoskeletal system and connective tissue

103

1.80

2.57

1.3

1.18

2.29

ml/s/173m2

0.82

Suicide or other Intentional self-harm

2.30

2.57

1.5

1.3

0.98

1.18

ml/s/173m2

0.33

Subjective visual disturbances

2.30

2.57

1.1

1.2

1.41

1.16

ml/s/173m2

0.53

Intracranial trauma

137

1.77

2.55

1.4

3.63

1.40

ml/s/173m2

0.42

Ischemic heart diseases

206

1.59

2.55

1.3

1.4

0.74

1.30

ml/s/173m2

4.01

134

Other diseases of anus and rectum

100

2.09

2.55

1.3

1.04

1.12

ml/s/173m2

0.12

STROKE

117

1.84

2.54

1.2

1.3

1.35

1.33

ml/s/173m2

0.02

Disorders of vitreous body

190

1.75

2.53

1.2

1.3

1.08

1.01

ml/s/173m2

0.09

122

Symptoms and signs involving the circulatory and respiratory systems

188

1.57

2.53

1.3

1.4

1.10

1.75

ml/s/173m2

0.85

124

Disorders of lens

168

1.66

2.50

1.2

1.3

0.89

1.18

ml/s/173m2

0.97

105

Asthma (mode)

125

1.72

2.50

1.3

1.4

1.03

1.24

ml/s/173m2

0.64

Statin medication

122

1.75

2.50

1.1

1.4

1.06

1.92

ml/s/173m2

0.69

Acute bronchitis

154

1.85

2.50

1.4

1.29

1.73

ml/s/173m2

0.37

102

Rheumatoid arthritis

2.09

2.49

1.4

0.57

1.97

ml/s/173m2

0.94

Diabetic retinopathy, excluding more controls

2.18

2.48

1.4

1.3

0.50

1.40

ml/s/173m2

2.58

Inflammatory bowel disease

109

2.02

2.45

1.3

1.55

1.83

ml/s/173m2

0.16

All anxiety disorders

167

1.72

2.44

1.4

1.3

1.35

1.81

ml/s/173m2

0.46

114

Malignant neoplasm of colon, including Hilmo

2.66

2.42

1.3

1.5

0.41

0.68

ml/s/173m2

—

Episodal and paroxysmal disorders

222

1.51

2.38

1.4

1.20

1.66

ml/s/173m2

0.65

151

Kela-code for severe mental illness

111

1.98

2.34

1.6

1.2

1.00

1.77

ml/s/173m2

0.61

Dysplasia of cervi uteri

2.72

2.34

1.2

1.3

11.16

1.39

ml/s/173m2

—

Dizziness and giddiness

243

1.57

2.29

1.4

1.3

1.14

1.46

ml/s/173m2

0.42

163

Dental operations

1.79

2.28

1.2

1.3

0.87

1.11

ml/s/173m2

0.73

Any mental disorder, or suicide (or attempt), or psychic disorders complicating pregnancy, partum or puerperium or nerve system disorders

2.12

2.28

1.5

1.3

1.03

2.00

ml/s/173m2

0.61

Gastro-oesophageal reflux disease

219

1.62

2.26

1.4

1.3

1.24

1.49

ml/s/173m2

0.23

141

Bacterial pneumonia (organism specified)

147

1.79

2.25

1.1

1.4

0.86

1.08

ml/s/173m2

0.64

Rheumatoid arthritis, including avohilmo

113

1.95

2.24

1.4

1.2

0.61

1.06

ml/s/173m2

1.68

Visual disturbances and blindness

209

1.67

2.21

1.5

1.3

1.17

1.60

ml/s/173m2

0.51

139

Other and unspecified tonsillitis

1.98

2.18

1.7

1.4

1.39

2.24

ml/s/173m2

0.47

Myocardial infarction

113

1.79

2.18

1.3

0.72

1.09

ml/s/173m2

0.71

Phlebitis and thrombophlebitis (not including DVT)

2.30

2.14

1.2

1.1

1.17

1.20

ml/s/173m2

—

Senile cataract

144

1.65

2.14

1.2

1.3

0.99

1.17

ml/s/173m2

0.46

Diseases of oral cavity, salivary glands and jaws

1.77

2.12

1.2

1.5

0.80

0.99

ml/s/173m2

0.49

Sub-endpoint used in defining T1D endpoints

107

1.93

2.10

1.3

0.54

1.33

ml/s/173m2

3.97

Caries of enamel

266

1.48

2.10

1.3

2.64

1.15

ml/s/173m2

0.62

177

Fibroblastic disorders

2.13

2.08

1.4

1.3

0.71

1.03

ml/s/173m2

—

Major coronary heart disease event excluding revascularizations

133

1.69

2.08

1.3

0.73

1.10

ml/s/173m2

0.88

Anxiety (asthma-related co-morbidities)

166

1.65

2.07

1.4

1.2

1.35

1.83

ml/s/173m2

0.47

110

Use of hypnotics and sedatives

260

1.45

2.07

1.2

1.3

1.10

1.48

ml/s/173m2

0.51

170

Bacterial pneumonia, not elsewhere classified

108

1.87

2.06

1.1

1.4

0.87

1.15

ml/s/173m2

0.71

Any mental disorder

223

1.46

2.05

1.4

1.3

1.05

1.55

ml/s/173m2

0.69

142

Bacterial pneumoniae

115

1.83

2.03

1.1

1.4

0.83

1.20

ml/s/173m2

1.13

Other anxiety disorders

130

1.77

2.03

1.4

1.3

1.16

1.94

ml/s/173m2

0.66

Asthma (only as main-diagnosis), excluding more controls

107

1.70

2.02

1.2

1.4

1.00

1.35

ml/s/173m2

1.13

HSIL lesion of the cervix uteri, vagina or vulva

2.50

2.01

1.1

1.2

10.19

1.25

ml/s/173m2

—

HSIL lesion of the cervix uteri

2.63

2.00

1.1

1.2

12.20

1.25

ml/s/173m2

—

Cardiodefibrillation

125

1.84

2.00

1.3

1.4

0.96

0.90

ml/s/173m2

0.07

All dysplastic lesions of the cervix uteri

2.29

1.97

1.2

1.3

8.81

1.26

ml/s/173m2

—

Soft tissue disorders

228

1.44

1.90

1.3

1.17

1.69

ml/s/173m2

0.77

147

Chronic periodontitis, including avohilmo

260

1.45

1.90

1.3

1.28

1.40

ml/s/173m2

0.14

167

Diabetic retinopathy

100

1.74

1.89

1.4

1.3

0.46

1.12

ml/s/173m2

3.40

Periodontitis

260

1.45

1.89

1.3

1.28

1.40

ml/s/173m2

0.14

167

Chronic periodontitis, complicated

221

1.59

1.89

1.3

1.12

1.08

ml/s/173m2

0.08

141

Other condition

2.39

1.85

1.6

1.2

1.32

1.13

ml/s/173m2

—

Substance abuse, excluding more controls

171

1.61

1.81

1.6

1.2

0.89

1.63

ml/s/173m2

0.79

107

Aortic aneurysm

2.01

1.81

1.3

0.93

0.92

ml/s/173m2

—

Other extrapyramidal and movement disorders in other diseases

2.00

1.79

1.3

1.53

1.02

ml/s/173m2

—

Conjunctivitis (acute, non atopic)

108

1.84

1.78

1.6

1.3

1.18

1.98

ml/s/173m2

0.60

Other acute lower respiratory infections

212

1.57

1.77

1.5

1.3

1.45

1.61

ml/s/173m2

0.15

145

Excessive attrition of teeth

245

1.53

1.75

1.2

1.3

3.87

1.26

ml/s/173m2

0.42

169

Calculus of kidney and ureter

117

1.80

1.73

1.3

1.47

0.98

ml/s/173m2

0.98

Secondary malignant neoplasm of respiratory and digestive organs, including Hilmo

2.22

1.73

1.6

1.4

1.67

0.74

ml/s/173m2

—

Thoracic aortic aneurysm

2.29

1.70

1.4

1.3

0.91

0.98

ml/s/173m2

—

Irritable bowel syndrome

2.00

1.69

1.3

1.2

0.94

2.36

ml/s/173m2

—

Degeneration of macula and posterior pole

113

1.71

1.68

1.3

0.68

0.97

ml/s/173m2

0.95

Injuries to the ankle and foot

262

1.47

1.66

1.3

1.13

1.64

ml/s/173m2

0.84

173

Syncope and collapse

117

1.71

1.66

1.3

0.62

1.16

ml/s/173m2

2.20

Fracture of lower leg, including ankle

215

1.55

1.66

1.2

1.3

0.85

1.49

ml/s/173m2

0.93

144

Psychiatric diseases

213

1.41

1.65

1.4

1.3

1.07

1.55

ml/s/173m2

0.62

137

Chronic rhinitis, nasopharyngitis and pharyngitis

112

1.79

1.63

1.4

1.3

1.37

1.25

ml/s/173m2

0.17

Dermatitis and eczema

294

1.37

1.63

1.2

1.4

1.46

1.44

ml/s/173m2

0.02

190

Injuries to the head

295

1.37

1.62

1.4

1.3

2.17

1.27

ml/s/173m2

0.37

190

Soft tissue disorders related to use, overuse and pressure

1.84

1.61

1.3

0.77

1.17

ml/s/173m2

0.69

Poisoning by medicine

2.06

1.59

1.9

1.3

0.53

1.25

ml/s/173m2

—

Poisoning by drugs, medicaments and biological substances

2.00

1.58

1.9

1.3

0.72

1.24

ml/s/173m2

—

Colorectal cancer, including Hilmo

2.01

1.58

1.2

1.4

0.40

0.81

ml/s/173m2

—

Triptan medication for migraine, single purchase ok

192

1.48

1.58

1.2

1.3

1.31

1.63

ml/s/173m2

0.33

128

Migraine, single triptan purchase ok & required. ICD-code if available is included

192

1.48

1.58

1.2

1.3

1.31

1.63

ml/s/173m2

0.33

128

Unspecified urinary incontinence

3.00

1.58

1.5

1.52

1.14

ml/s/173m2

—

Schizophrenia or delusion, excluding more controls

1.88

1.54

1.7

1.2

1.07

2.08

ml/s/173m2

—

Other diseases of upper respiratory tract

252

1.36

1.53

1.4

1.3

1.12

1.18

ml/s/173m2

0.15

164

Other necrotizing vasculopathies (FG)

3.34

1.52

2.2

1.3

0.49

0.90

ml/s/173m2

—

Benign neoplasms

227

1.39

1.52

1.2

1.4

2.23

1.32

ml/s/173m2

0.37

137

Use of rivastigmine

0.00

1.52

0.0

1.2

—

0.70

—

Concussion

136

1.60

1.50

1.5

1.4

4.14

1.40

ml/s/173m2

0.42

Other and unspecified dermatitis

209

1.53

1.50

1.3

1.4

1.48

1.57

ml/s/173m2

0.06

137

Diseases of vocal cords and larynx+other diseases of upper respiratory tract, no elsewhere classified

209

1.52

1.50

1.2

1.3

1.59

1.08

ml/s/173m2

0.71

134

Conduction disorders

1.89

1.50

1.1

1.4

1.00

1.26

ml/s/173m2

—

Endometriosis

2.03

1.49

1.4

1.3

2.26

1.26

ml/s/173m2

—

Noninfective enteritis and colitis

193

1.55

1.49

1.3

1.44

1.68

ml/s/173m2

0.24

132

Depression

259

1.39

1.49

1.4

1.3

1.25

1.50

ml/s/173m2

0.29

164

Other disorders of bone

2.07

1.49

1.2

1.3

1.98

1.21

ml/s/173m2

—

Extrapyramidal and movement disorders

131

1.68

1.49

1.3

1.40

0.96

ml/s/173m2

—

111

1.70

1.46

1.2

1.3

0.97

0.74

ml/s/173m2

0.40

Disorders of breast

122

1.66

1.46

1.2

1.4

0.98

1.92

ml/s/173m2

0.68

Unintentional cut, puncture, perforation or haemorrhage during surgical and medical care

2.73

1.43

2.0

1.3

0.80

0.88

ml/s/173m2

—

Asthma-related pneumonia

140

1.64

1.42

1.3

1.4

0.93

1.15

ml/s/173m2

0.61

Primary coxarthrosis, bilateral

1.79

1.42

1.2

1.3

0.79

0.89

ml/s/173m2

—

Asthma-related pneumonia or sepsis

140

1.64

1.42

1.3

1.4

0.93

1.15

ml/s/173m2

0.61

Asthma, hospital admissions 3, pneumonia

140

1.64

1.42

1.3

1.4

0.93

1.15

ml/s/173m2

0.61

Female infertility

2.12

1.42

1.5

1.3

1.99

1.33

ml/s/173m2

—

Urolithiasis

126

1.67

1.39

1.3

1.47

0.95

ml/s/173m2

1.06

Other infectious diseases, including avohilmo

2.42

1.39

1.0

1.3

1.96

0.86

ml/s/173m2

—

Biguanides

227

1.38

1.37

1.4

1.3

1.31

1.48

ml/s/173m2

0.14

148

Symptoms and signs involving cognition, perception, emotional state and behaviour

275

1.36

1.37

1.4

1.3

1.28

1.42

ml/s/173m2

0.17

181

Asthma (only as main-diagnosis)

122

1.51

1.35

1.2

1.4

1.00

1.25

ml/s/173m2

0.74

Mycoses, including avohilmo

302

1.36

1.35

1.2

1.4

2.74

1.18

ml/s/173m2

0.54

195

Other functional intestinal disorders

173

1.52

1.33

1.3

1.4

1.07

1.84

ml/s/173m2

0.76

110

Other CVD

1.97

1.32

1.2

1.3

0.52

0.92

ml/s/173m2

—

Transient ischemic attack

145

1.54

1.32

1.4

1.3

0.97

0.90

ml/s/173m2

0.10

Visual disturbances

200

1.50

1.31

1.4

1.3

1.33

1.63

ml/s/173m2

0.29

131

Finngen Rheumatological endpoints

215

1.37

1.31

1.4

1.3

1.09

1.68

ml/s/173m2

0.85

143

Open wound of head

219

1.46

1.29

1.4

1.3

0.95

1.25

ml/s/173m2

1.09

141

Colorectal cancer

1.95

1.29

1.2

1.5

0.40

0.74

ml/s/173m2

—

Behavioural and emotional disorders with onset usually occurring in childhood and adolescence

1.85

1.28

1.4

1.82

1.66

ml/s/173m2

—

Diseases of salivary glands

1.72

1.26

1.4

1.3

1.27

1.14

ml/s/173m2

0.16

Pain in joint

127

1.50

1.26

1.2

1.4

1.15

1.23

ml/s/173m2

0.14

Chronic apical periodontitis

253

1.33

1.25

1.2

1.4

1.12

1.52

ml/s/173m2

0.53

159

Cerebrovascular diseases

202

1.41

1.25

1.2

1.3

1.04

1.08

ml/s/173m2

0.08

128

1.79

1.24

1.5

1.3

0.46

0.79

ml/s/173m2

—

Developmental endpoint to exclude non autoimmune-cases from E4_HYTHY_AI_STRICT

115

1.65

1.24

1.7

1.3

1.48

1.27

ml/s/173m2

0.28

Dermatitis

255

1.42

1.24

1.2

1.4

1.46

ml/s/173m2

0.00

166

Strabismus

100

1.70

1.22

1.6

1.3

1.25

1.41

ml/s/173m2

—

Hypothyroidism, strict autoimmune

159

1.44

1.21

1.6

1.3

1.33

1.67

ml/s/173m2

0.22

104

Actinic keratosis

105

1.65

1.21

1.2

1.3

0.82

0.71

ml/s/173m2

0.15

All dysplastic lesions of the cervix uteri, vagina or vulva

1.84

1.19

1.2

1.3

8.81

1.22

ml/s/173m2

—

Disorders of sclera, cornea, iris and ciliary body

213

1.46

1.19

1.3

0.90

1.59

ml/s/173m2

1.00

145

Myocardial infarction, strict

109

1.56

1.19

1.3

0.74

1.06

ml/s/173m2

0.49

Other infectious diseases

2.31

1.18

1.0

1.3

1.94

0.86

ml/s/173m2

—

Cholecystectomy

230

1.40

1.18

1.3

1.11

1.44

ml/s/173m2

0.39

149

Other external causes of accidental injury

172

1.37

1.17

1.3

1.4

1.05

1.32

ml/s/173m2

0.87

109

0.00

1.16

0.0

1.5

—

2.02

—

Codeine or tramadol medication

253

1.31

1.16

1.3

1.24

1.43

ml/s/173m2

0.20

160

Injuries to unspecified part of trunk, limb or body region

0.00

1.15

0.0

1.4

—

1.04

—

In situ neoplasms

126

1.59

1.14

1.5

1.3

0.94

1.61

ml/s/173m2

0.43

Mental and behavioural disorders due to psychoactive substance use

228

1.41

1.12

1.6

1.2

0.86

1.58

ml/s/173m2

1.10

148

Skin changes due to chronic exposure to nonionizing radiation

107

1.61

1.12

1.2

1.3

0.82

0.70

ml/s/173m2

0.17

Benign neoplasm: Colon, unspecified

1.71

1.11

1.1

1.3

1.24

0.90

ml/s/173m2

—

Procreative management

117

1.55

1.10

1.3

2.06

1.40

ml/s/173m2

0.80

Ventral hernia

1.78

1.10

1.0

1.4

0.91

1.02

ml/s/173m2

—

Enthesopathies of lower limb, excluding foot

1.78

1.10

1.2

1.3

1.48

1.18

ml/s/173m2

—

Speech therapy

1.73

1.08

1.1

1.3

1.22

1.09

ml/s/173m2

—

Arthropathies

185

1.34

1.08

1.2

1.4

1.07

1.78

ml/s/173m2

0.96

126

Benign neoplasm: Transverse colon

2.19

1.08

1.0

1.3

1.17

0.93

ml/s/173m2

—

Falls/tendency to fall

236

1.29

1.07

1.2

1.4

2.38

1.29

ml/s/173m2

0.39

153

Pregnancy hypertension

100

1.61

1.07

1.3

1.2

1.08

2.17

ml/s/173m2

—

Disorders of ocular muscles, binocular movement, accommodation and refraction

201

1.43

1.05

1.4

1.3

1.43

1.71

ml/s/173m2

0.25

142

Other specific joint derangements/joint disorders

172

1.38

1.04

1.1

1.4

1.20

1.77

ml/s/173m2

0.61

117

Epilepsy

113

1.59

1.04

1.4

1.3

1.01

1.38

ml/s/173m2

—

Accidents

172

1.34

1.03

1.3

1.4

1.00

1.32

ml/s/173m2

1.13

109

Stroke, including SAH

175

1.39

1.03

1.2

1.3

1.12

0.98

ml/s/173m2

0.28

112

Substance abuse

221

1.39

1.01

1.6

1.2

0.89

1.53

ml/s/173m2

0.93

147

Benign neoplasm: Caecum

2.00

1.00

1.7

1.3

0.56

0.81

ml/s/173m2

—

187

1.43

0.99

1.4

1.3

1.14

1.82

ml/s/173m2

0.83

123

Asthma, hospital admission 2, infections

250

1.36

0.98

1.3

1.08

1.62

ml/s/173m2

0.90

169

Asthma-related infections

250

1.36

0.98

1.3

1.08

1.62

ml/s/173m2

0.90

169

Intracranial injury

231

1.37

0.98

1.5

1.3

3.79

1.24

ml/s/173m2

0.47

149

Injuries to the knee and lower leg

288

1.26

0.97

1.3

1.4

1.19

1.51

ml/s/173m2

0.45

186

Stroke, excluding SAH

166

1.39

0.97

1.2

1.3

1.16

0.94

ml/s/173m2

0.44

105

Schizophrenia or delusion

100

1.60

0.96

1.7

1.2

1.07

1.14

ml/s/173m2

—

Glucagon-like peptide-1 (GLP-1) analogues

108

1.57

0.96

1.1

1.2

1.51

1.22

ml/s/173m2

—

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

108

1.57

0.96

1.1

1.2

1.51

1.22

ml/s/173m2

—

Pacemaker

115

1.54

0.96

1.2

1.3

0.33

0.88

ml/s/173m2

—

Disorders of conjunctiva

273

1.30

0.95

1.3

1.27

1.56

ml/s/173m2

0.43

179

Abrasion of teeth

125

1.52

0.93

1.1

1.2

1.34

1.78

ml/s/173m2

0.27

Vestibular neuronitis

2.22

0.93

1.2

1.3

0.83

0.91

ml/s/173m2

—

Schizophrenia, schizotypal and delusional disorders

101

1.58

0.93

1.7

1.2

1.07

1.14

ml/s/173m2

—

Diseases of pulp and periapical tissues and dental caries

118

1.39

0.92

1.2

1.3

0.91

1.24

ml/s/173m2

1.04

Insomnia

261

0.72

0.92

1.3

1.39

1.47

ml/s/173m2

0.08

166

Diseases of inner ear

192

1.39

0.91

1.5

1.3

1.15

1.43

ml/s/173m2

0.26

124

Other joint disorders

180

1.30

0.88

1.1

1.4

1.34

1.77

ml/s/173m2

0.46

123

Migraine

137

1.42

0.87

1.2

1.3

1.35

1.98

ml/s/173m2

0.53

Fall on same level involving ice and snow

237

1.35

0.87

1.3

1.13

1.49

ml/s/173m2

0.44

154

Dental caries, including avohilmo

137

1.35

0.86

1.2

1.3

0.96

1.22

ml/s/173m2

0.80

Injury, poisoning and certain other consequences of external causes

104

1.40

0.86

1.2

1.4

1.02

1.40

ml/s/173m2

1.17

Hypothyroidism, other/unspecified

235

1.29

0.85

1.5

1.3

1.41

1.50

ml/s/173m2

0.07

160

Contact with and exposure to communicable diseases

103

1.55

0.85

1.3

1.56

2.18

ml/s/173m2

—

Gingivitis and periodontal diseases

211

1.27

0.85

1.3

1.4

1.15

1.53

ml/s/173m2

0.49

144

Disorders of vestibular function (Vertigo)

157

1.43

0.85

1.5

1.3

1.05

0.99

ml/s/173m2

0.09

Diseases of middle ear and mastoid

173

1.37

0.84

1.6

1.3

1.22

1.72

ml/s/173m2

0.50

118

Angina pectoris

123

1.40

0.83

1.3

1.4

0.82

1.19

ml/s/173m2

0.86

Pregnancy with abortive outcome

1.41

0.82

1.2

1.4

1.09

2.13

ml/s/173m2

0.57

Rotator cuff syndrome

181

0.68

0.82

1.7

1.3

1.04

1.57

ml/s/173m2

0.51

113

Hypothyreosis and Thyroxine purchase for inclusion criteria

243

1.27

0.79

1.5

1.3

1.41

1.47

ml/s/173m2

0.05

164

Multiple delivery

0.00

0.79

0.0

1.3

—

1.10

—

Vascular dementia

0.00

0.78

0.0

1.3

—

0.58

—

Acetic acid derivatives and related substances

1.49

0.78

1.3

1.2

0.94

0.88

ml/s/173m2

0.10

Other complications of labour and delivery, not elsewhere classified

0.00

0.78

0.0

1.4

—

5.08

—

Other disorders of eyelid

147

1.41

0.78

1.2

1.4

1.50

0.91

ml/s/173m2

0.60

Combinations of oral blood glucose lowering drugs

1.53

0.78

1.1

1.3

1.22

1.07

ml/s/173m2

—

Other symptoms and signs involving cognitive functions and awareness

153

1.39

0.78

1.5

1.3

1.14

0.97

ml/s/173m2

0.27

103

Disorders of refraction and accommodation

114

1.49

0.78

1.6

1.4

1.62

1.41

ml/s/173m2

—

Injury of unspecified body region

0.00

0.77

0.0

1.4

—

1.01

—

Open wound of wrist and hand

184

1.37

0.77

1.5

1.3

0.97

1.62

ml/s/173m2

0.79

126

Sleep disorders (combined)

250

1.23

0.77

1.3

1.4

1.05

1.54

ml/s/173m2

0.76

161

Sleep disorders

264

0.76

0.75

1.3

1.38

1.49

ml/s/173m2

0.11

170

Allergic rhinitis

114

1.47

0.75

1.1

1.3

1.15

2.19

ml/s/173m2

0.90

Unspecified fall

205

1.34

0.75

1.4

1.3

3.36

1.22

ml/s/173m2

0.40

142

Parasetamol

144

1.30

0.73

1.3

1.25

1.29

ml/s/173m2

0.08

Coronary atherosclerosis

142

1.33

0.73

1.2

1.4

0.73

1.20

ml/s/173m2

1.61

Conjunctivitis

254

1.27

0.71

1.3

1.27

1.60

ml/s/173m2

0.48

169

Hyperplasia of prostate

1.39

0.71

1.2

1.3

1.09

1.17

ml/s/173m2

0.11

Diabetes mellitus in pregnancy

1.56

0.69

1.4

1.3

1.07

3.03

ml/s/173m2

—

Dental pulpitis, including avohilmo

270

0.78

0.68

1.3

1.10

1.50

ml/s/173m2

0.61

178

COPD (mode)

1.54

0.67

1.5

1.4

1.26

1.06

ml/s/173m2

—

Injuries to the elbow and forearm

258

1.26

0.67

1.3

1.32

1.55

ml/s/173m2

0.23

171

Chronic sinusitis

144

1.39

0.67

1.3

1.2

1.17

1.11

ml/s/173m2

0.09

Excessive earwax

257

0.74

0.66

1.3

1.37

1.15

ml/s/173m2

0.45

170

Other hearing loss

1.49

0.66

1.1

1.3

1.65

0.82

ml/s/173m2

—

Keratitis

120

1.42

0.64

1.3

0.99

1.80

ml/s/173m2

0.63

Injury of muscle and tendon at hip and thigh level

1.72

0.64

1.2

1.23

1.02

ml/s/173m2

—

Other noninfective gastroenteritis and colitis

1.47

0.63

1.4

1.3

1.61

1.41

ml/s/173m2

—

External causes of morbidity and mortality

129

1.28

0.62

1.1

1.3

1.05

1.43

ml/s/173m2

1.32

Maternal care related to the fetus and amniotic cavity and possible delivery problems

1.41

0.61

1.1

1.2

0.96

1.49

ml/s/173m2

1.41

Depression or dysthymia

151

1.27

0.61

1.3

1.4

1.07

1.68

ml/s/173m2

0.52

Other peripheral vascular diseases

0.00

0.60

0.0

1.4

—

0.83

—

Spontaneous rupture of synovium and tendon

0.00

0.60

0.0

1.2

—

0.91

—

Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium

113

1.38

0.59

1.3

1.22

1.96

ml/s/173m2

—

Injuries to the thorax

183

1.31

0.59

1.3

0.99

1.09

ml/s/173m2

0.18

125

Dentofacial anomalies [including malocclusion]

213

1.25

0.57

1.6

1.3

3.48

1.23

ml/s/173m2

0.54

144

Obesity related asthma

132

1.36

0.56

1.4

1.3

0.79

1.19

ml/s/173m2

—

Triptan medication for migraine, min. 3 purchases

144

1.30

0.56

1.3

1.39

1.87

ml/s/173m2

0.38

Other symptoms and signs involving the nervous and musculoskeletal systems

159

1.32

0.55

1.4

1.3

1.31

1.60

ml/s/173m2

0.23

106

Abnormal serum enzyme levels

129

1.35

0.53

1.3

1.23

0.98

ml/s/173m2

0.64

Nerve, nerve root and plexus disorders

275

1.18

0.52

1.2

1.3

0.99

1.48

ml/s/173m2

0.79

169

Fracture at wrist and hand level

134

1.34

0.52

1.2

1.3

1.40

1.26

ml/s/173m2

0.17

Diseases of male genital organs

125

1.25

0.50

1.2

1.3

1.08

1.37

ml/s/173m2

0.74

Exclusions for E4_PCOS_CONSORTIUM

167

1.23

0.50

1.5

1.3

1.44

1.85

ml/s/173m2

0.38

111

Medical abortion

1.30

0.50

1.2

1.4

1.11

2.13

ml/s/173m2

0.56

Ischaemic Stroke, excluding all haemorrhages

158

1.26

0.49

1.3

0.85

0.92

ml/s/173m2

0.11

Inguinal hernia

155

1.24

0.48

1.2

1.3

1.23

1.12

ml/s/173m2

0.17

100

Low back pain

219

1.20

0.48

1.2

1.4

1.08

1.54

ml/s/173m2

0.59

141

Meniscus derangement

131

1.27

0.47

1.6

1.4

1.25

1.78

ml/s/173m2

0.39

Organic, including symptomatic, mental disorders

133

0.74

0.47

1.4

1.3

1.27

0.87

ml/s/173m2

—

Arthrosis

143

1.23

0.46

1.2

1.4

1.17

1.75

ml/s/173m2

0.50

Disorders of skin appendages

191

1.25

0.44

1.3

1.16

1.73

ml/s/173m2

0.62

127

Injuries to the shoulder and upper arm

296

1.17

0.44

1.3

2.77

1.18

ml/s/173m2

0.49

191

Psoriasis

1.37

0.43

1.3

2.51

1.08

ml/s/173m2

—

Behavioural syndromes associated with physiological disturbances and physical factors

282

0.84

0.43

1.4

1.3

1.40

1.49

ml/s/173m2

0.11

182

Vasomotor and allergic rhinitis

136

1.29

0.43

1.1

1.3

1.16

1.43

ml/s/173m2

0.56

Mental and behavioural disorders due to alcohol

201

1.23

0.43

1.7

1.3

0.73

1.16

ml/s/173m2

1.05

135

Dorsalgia

223

1.16

0.42

1.1

1.4

1.21

1.55

ml/s/173m2

0.40

143

Conjunctivitis (acute, non atopic), including avohilmo

290

0.85

0.42

1.5

1.3

3.01

1.25

ml/s/173m2

0.48

189

Other antidepressants

220

1.16

0.41

1.4

1.3

1.13

1.49

ml/s/173m2

0.41

133

Persons encountering health services in circumstances related to reproduction

172

1.21

0.41

1.3

1.64

1.37

ml/s/173m2

0.30

124

Striking against or struck by other objects

140

1.28

0.41

1.3

1.4

1.06

1.31

ml/s/173m2

—

105

Ischaemic heart disease, wide definition

192

1.19

0.41

1.2

1.4

0.73

1.15

ml/s/173m2

1.57

128

Toxic effect of contact with venomous animals

0.00

0.40

0.0

1.4

—

0.99

—

Sequelae of other external causes

0.00

0.40

0.0

1.3

—

0.86

—

Lower back pain or/and sciatica

287

1.15

0.40

1.2

1.4

1.06

1.44

ml/s/173m2

0.63

184

Chronic diseases of tonsils and adenoids

215

1.17

0.39

1.4

1.3

3.06

1.27

ml/s/173m2

0.47

145

Mouth breathing

177

1.24

0.39

1.5

1.3

1.41

1.32

ml/s/173m2

0.10

125

Disorders of synovium and tendon

183

0.79

0.39

1.1

1.3

1.00

1.57

ml/s/173m2

0.58

117

Hypothyroidism, strict autoimmune, 3 medication purchases required

217

1.18

0.39

1.5

1.3

1.16

1.45

ml/s/173m2

0.24

146

Use of galantamine

0.00

0.39

0.0

1.3

—

0.60

—

Temporomandibular joint disorders, including avohilmo

137

1.27

0.39

1.4

1.2

6.01

1.25

ml/s/173m2

0.53

Diseases of the ear and mastoid process

260

1.14

0.38

1.4

1.3

1.35

1.51

ml/s/173m2

0.20

167

Hypermetropia

1.35

0.37

1.6

1.5

—

1.40

—

Disorders of the thyroid gland

260

1.15

0.36

1.4

1.3

1.15

1.45

ml/s/173m2

0.38

173

Injuries to the wrist and hand

310

1.13

0.35

1.4

1.3

1.20

1.50

ml/s/173m2

0.46

199

Fracture of rib(s), sternum and thoracic spine

117

1.28

0.35

1.2

1.3

1.15

0.99

ml/s/173m2

—

Leiomyoma of uterus

113

0.79

0.34

1.0

1.4

1.20

1.97

ml/s/173m2

—

Sensorineural hearing loss

225

1.15

0.34

1.4

1.3

1.38

1.04

ml/s/173m2

1.01

148

Tonsillectomy and adenotomy

164

1.19

0.33

1.4

1.3

3.68

1.46

ml/s/173m2

0.42

119

Other spirochaetal diseases

109

1.28

0.33

1.3

0.87

1.06

ml/s/173m2

—

Other disorders of veins

134

1.25

0.33

1.4

1.3

0.88

1.64

ml/s/173m2

—

Contraceptive management

101

1.25

0.33

1.3

1.38

1.21

ml/s/173m2

0.20

Disorders of lacrimal system

161

1.22

0.32

1.5

1.3

1.48

1.45

ml/s/173m2

0.02

103

Disorders of eyelid, lacrimal system and orbit

283

1.14

0.32

1.4

1.3

1.48

1.42

ml/s/173m2

0.05

184

Other fall from one level to another

0.67

0.32

1.0

1.4

1.13

1.33

ml/s/173m2

—

Unspecific neurodegenerative disorder

0.75

0.32

1.3

0.40

0.75

ml/s/173m2

—

Coxarthrosis

117

1.21

0.32

1.0

1.4

1.16

ml/s/173m2

0.00

Lumbar disc prolapse

203

0.84

0.31

1.2

1.3

1.06

1.55

ml/s/173m2

0.56

130

Shoulder lesions

190

0.85

0.31

1.2

1.3

1.08

1.58

ml/s/173m2

0.52

120

Other headache syndromes

137

1.24

0.31

1.2

1.3

1.36

1.87

ml/s/173m2

—

Fracture of femur

1.32

0.31

1.6

1.4

0.85

0.86

ml/s/173m2

—

COPD, hospital admission 2, with asthma infections

103

1.25

0.30

1.3

1.16

0.87

ml/s/173m2

—

Other spirochaetal diseases, including avohilmo

111

1.26

0.30

1.3

0.87

1.08

ml/s/173m2

—

Other arthrosis

129

1.19

0.30

1.1

1.4

1.01

1.20

ml/s/173m2

0.52

Spondylosis

178

0.83

0.28

1.3

0.99

1.12

ml/s/173m2

—

112

Alcohol use disorder, ICD-based

167

1.20

0.28

1.8

1.2

0.45

1.15

ml/s/173m2

2.57

112

Conductive and sensorineural hearing loss

241

1.13

0.28

1.4

1.3

1.37

1.09

ml/s/173m2

0.80

159

Coxarthrosis, primary, with hip surgery

155

1.20

0.28

1.2

1.4

0.74

1.03

ml/s/173m2

0.76

101

Nonsuppurative otitis media, including avohilmo

1.26

0.27

1.9

1.2

1.59

1.44

ml/s/173m2

—

Asthma (diagnoses ohter than nonallergic)

317

1.12

0.27

1.4

1.3

0.95

1.52

ml/s/173m2

1.22

206

Malignant neoplasm of breast, HER2-negative

1.25

0.27

1.5

1.4

1.28

1.33

ml/s/173m2

—

Malignant neoplasm of breast

1.25

0.27

1.5

1.4

1.28

1.33

ml/s/173m2

—

Other and unspecified disorders of vitreous body

155

1.20

0.27

1.2

1.4

1.56

1.00

ml/s/173m2

0.55

101

Spondylopathies

197

0.87

0.26

1.3

0.85

1.57

ml/s/173m2

0.98

127

Diseases of appendix

287

0.87

0.26

1.5

1.3

1.17

1.44

ml/s/173m2

0.35

181

Coxarthrosis [arthrosis of hip](FG)

141

1.17

0.26

1.0

1.3

1.00

1.18

ml/s/173m2

0.35

Necrosis of pulp, including avohilmo

243

0.85

0.26

1.0

1.3

1.76

1.53

ml/s/173m2

0.13

165

Gestational diabetes (for exclusion)

1.27

0.26

1.4

1.3

1.32

2.52

ml/s/173m2

—

Caries of dentine, including avohilmo

167

1.13

0.25

1.3

0.98

1.84

ml/s/173m2

1.02

108

Other abnormal products of conception

1.27

0.25

1.1

1.3

0.77

2.86

ml/s/173m2

—

Asthma, including avohilmo

315

0.91

0.25

1.4

1.3

1.09

1.51

ml/s/173m2

0.79

206

Glaucoma

176

1.16

0.24

1.1

1.4

1.10

0.99

ml/s/173m2

0.24

116

Non-allergic asthma (mode), excluding more controls

1.34

0.23

1.8

1.4

1.22

1.52

ml/s/173m2

—

Gonarthrosis [arthrosis of knee](FG)

168

1.13

0.23

1.3

0.97

1.71

ml/s/173m2

0.78

108

Selective serotonin reuptake inhibitors

226

1.10

0.23

1.3

1.23

1.51

ml/s/173m2

0.31

139

Lyme disease, including avohilmo

106

1.23

0.23

1.3

0.81

1.05

ml/s/173m2

—

Lyme disease

106

1.23

0.23

1.3

0.81

1.05

ml/s/173m2

—

Gonarthrosis, primary, with knee surgery

184

1.14

0.23

1.4

1.3

0.95

1.05

ml/s/173m2

0.16

116

Appendicitis, broad definition

284

0.88

0.22

1.5

1.3

1.17

1.46

ml/s/173m2

0.38

178

Symptoms and signs involving the nervous and musculoskeletal systems

247

1.13

0.22

1.4

1.3

1.34

1.52

ml/s/173m2

0.20

166

Artrosis, including avohilmo

197

1.11

0.22

1.1

1.4

1.19

1.56

ml/s/173m2

0.39

128

Acute appendicitis

273

0.88

0.21

1.5

1.3

1.21

1.48

ml/s/173m2

0.34

173

Spirochaetal infections, other/unspecified, including avohilmo

107

1.22

0.21

1.3

0.81

1.05

ml/s/173m2

—

Alcohol abuse, main dg, excluding more controls

1.19

0.21

1.2

1.45

1.15

ml/s/173m2

—

Non-allergic asthma (mode)

1.18

0.21

1.8

1.3

1.22

1.42

ml/s/173m2

—

Fracture of shoulder and upper arm

135

1.18

0.21

1.7

1.4

1.62

1.15

ml/s/173m2

—

COPD related to multimorbidity

122

1.18

0.21

1.4

1.3

1.16

0.96

ml/s/173m2

—

Other chronic obstructive pulmonary disease, including avohilmo

180

0.87

0.20

1.6

1.3

1.16

0.98

ml/s/173m2

—

116

Malignant neoplasm of stomach, including Hilmo

0.00

0.20

0.0

1.4

—

0.80

—

Fracture of forearm

198

1.13

0.20

1.3

1.4

1.39

1.53

ml/s/173m2

0.09

133

Other diseases of lip and oral mucosa

164

1.16

0.20

1.3

6.32

1.16

ml/s/173m2

0.53

110

Other dorsopathies, not elsewhere classified

223

1.09

0.20

1.2

1.4

1.16

1.55

ml/s/173m2

0.47

143

Other maternal disorders predominantly related to pregnancy

108

1.16

0.20

1.1

1.4

1.28

2.01

ml/s/173m2

0.34

Dislocation, sprain and strain of joints and ligaments of knee

226

0.88

0.19

1.1

1.3

1.82

1.57

ml/s/173m2

0.17

148

Malignant neoplasm of skin, including Hilmo

129

1.14

0.19

1.1

1.4

1.08

1.09

ml/s/173m2

0.03

Gonarthrosis,primary

237

1.09

0.19

1.3

0.81

1.11

ml/s/173m2

1.01

151

Transport accidents

153

1.14

0.18

1.4

1.3

0.96

1.34

ml/s/173m2

0.88

Asthma, hospital admissions , main diagnosis only

315

0.91

0.17

1.2

1.3

1.00

1.52

ml/s/173m2

1.03

203

Injuries to the hip and thigh

167

1.13

0.16

1.4

1.3

1.07

1.03

ml/s/173m2

0.04

114

Mental and behavioural disorders due to alcohol, excluding acute intoxication

185

1.12

0.16

1.8

1.2

0.55

1.13

ml/s/173m2

1.84

123

Dorsopathies

231

1.07

0.15

1.2

1.4

1.33

1.58

ml/s/173m2

0.28

149

Myocardial infarction, without ST-elevation

126

1.15

0.15

1.4

0.75

0.93

ml/s/173m2

—

Other disorders of lacrimal gland

121

1.16

0.15

1.6

1.3

1.58

1.69

ml/s/173m2

—

Asthma/COPD (KELA code 203)

301

0.93

0.14

1.2

1.3

1.10

1.54

ml/s/173m2

0.80

196

Urticaria and erythema

139

0.86

0.14

1.1

1.3

1.54

1.88

ml/s/173m2

—

100

Cervical disc disorders

141

1.13

0.13

1.1

1.3

1.25

1.14

ml/s/173m2

—

Inflammatory diseases of female pelvic organs

130

1.10

0.12

1.4

0.94

1.87

ml/s/173m2

0.72

Atopic dermatitis

190

1.09

0.12

1.2

1.3

1.76

1.74

ml/s/173m2

0.01

126

Dermatophytosis, including avohilmo

263

1.08

0.11

1.1

1.3

3.79

1.19

ml/s/173m2

0.52

168

Malignant neoplasm of breast, HER2-negative, including Hilmo

1.14

0.11

1.1

1.4

1.44

1.36

ml/s/173m2

—

Malignant neoplasm of breast, including Hilmo

1.14

0.11

1.1

1.4

1.44

1.36

ml/s/173m2

—

Blepharochalasis

1.15

0.10

1.4

1.3

1.89

0.89

ml/s/173m2

—

Benign neoplasm: Skin of eyelid, including canthus

1.14

0.10

1.2

1.3

1.43

0.85

ml/s/173m2

—

Periapical abscess

197

0.91

0.09

1.2

1.3

1.26

1.27

ml/s/173m2

—

132

Use of eye-antiallergens (taken as indicator of allergic/atopic conjunctivitis)

185

1.09

0.09

1.0

1.3

1.47

1.66

ml/s/173m2

0.16

119

Other inflammation of eyelid

1.06

0.09

1.0

1.2

1.88

1.05

ml/s/173m2

—

Congenital malformations and deformations of the musculoskeletal system

1.06

0.09

1.2

1.4

1.61

1.62

ml/s/173m2

—

Otitis media, unspecified

1.05

0.09

1.6

1.2

1.92

1.55

ml/s/173m2

—

Other intervertebral disc disorders

208

1.06

0.09

1.2

1.3

0.99

1.55

ml/s/173m2

0.71

133

Primary gonarthrosis, bilateral

181

0.92

0.08

1.4

1.3

0.75

1.05

ml/s/173m2

0.57

115

Malignant neoplasm of skin

119

1.08

0.07

1.1

1.4

1.08

1.06

ml/s/173m2

0.03

Sciatica+with lumbago

188

0.94

0.05

1.2

1.3

0.97

1.59

ml/s/173m2

0.69

120

Injury of muscle and tendon at shoulder and upper arm level

141

0.92

0.05

1.2

1.3

1.30

1.07

ml/s/173m2

—

Malignant neoplasm of prostate, including Hilmo

1.09

0.05

1.6

1.4

0.65

0.91

ml/s/173m2

—

Allergic conjunctivitis

200

1.06

0.05

1.0

1.3

1.38

1.61

ml/s/173m2

0.21

132

Chronic lower respiratory diseases

302

1.03

0.04

1.3

1.07

1.55

ml/s/173m2

0.97

197

Gonarthrosis

135

1.05

0.03

1.3

1.4

1.03

1.77

ml/s/173m2

0.61

Disease of hard tissues of teeth, NOS

0.94

0.03

1.2

1.4

0.75

0.99

ml/s/173m2

0.54

Other enthesopathies

112

1.07

0.02

1.2

1.3

1.67

1.89

ml/s/173m2

—

Other disorders of ear

285

1.02

0.01

1.4

1.3

1.40

1.45

ml/s/173m2

0.06

190

Diseases of pulp and periapical tissues, including avohilmo

244

1.02

0.01

1.3

1.4

1.07

1.61

ml/s/173m2

0.91

164

malignant neoplasm of male genital organs, including Hilmo

1.05

0.01

1.6

1.4

0.65

0.96

ml/s/173m2

—

Other/unspecified dorsalgia

142

1.04

0.01

1.2

1.4

1.57

1.78

ml/s/173m2

—

Carpal tunnel syndrome

220

1.02

0.00

1.5

1.3

0.88

1.53

ml/s/173m2

0.82

137

Coxarthrosis, primary

200

1.00

0.00

1.1

1.4

0.83

1.04

ml/s/173m2

0.42

126

COPD, hospital admissions 1, only main diagnosis

103

1.00

0.00

1.6

1.3

1.06

0.82

ml/s/173m2

—

COPD

144

1.01

0.00

1.4

1.3

1.06

0.98

ml/s/173m2

0.12

Artificial joint operation, meniscal resection

259

1.01

0.00

1.4

1.3

0.92

1.10

ml/s/173m2

0.44

166

COPD, hospital admissions

146

0.98

0.00

1.4

1.3

1.16

0.96

ml/s/173m2

—

COPD, early/later onset

147

0.97

0.00

1.4

1.3

1.16

0.97

ml/s/173m2

—

Appendectomy

245

1.01

0.00

1.3

1.41

1.51

ml/s/173m2

0.10

159

Papulosquamous disorders

149

1.01

0.00

1.7

1.3

2.17

1.12

ml/s/173m2

—

104

Deviated nasal septum

125

1.04

0.00

1.2

1.3

1.71

1.03

ml/s/173m2

—

Diseases of external ear

138

1.01

0.00

1.5

1.3

1.65

1.17

ml/s/173m2

—

Other chronic obstructive pulmonary disease

139

1.00

0.00

1.4

1.3

1.16

0.99

ml/s/173m2

—

Varicose veins

162

1.03

0.00

1.5

1.3

0.91

1.00

ml/s/173m2

—

103

Bursitis of shoulder

0.00

-0.00

0.0

1.4

—

0.71

—

Right ventricular outflow tract obstruction

0.00

-0.00

0.0

2.4

—

1.46

—

Congenital malformations and deformations of the musculoskeletal system, including avohilmo

0.92

-0.00

1.2

1.4

1.61

1.57

ml/s/173m2

—

Alcohol abuse, main dg

0.89

-0.00

1.2

1.3

1.45

1.06

ml/s/173m2

—

Congenital malformations of pulmonary and tricuspid valves

0.00

-0.00

0.0

2.3

—

1.48

—

Birth asphyxia

0.00

-0.00

0.0

1.6

—

1.85

—

≡ Risteys

R14

FinnGen R13 + FinRegistry

FinnGen R12 + FinRegistry

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood

Coding

Definition

OMOP mapping QC

Cohort

Year of birth distribution

Age at first measurement

Age at last measurement

Age at start of registry

Duration from first to last measurement

Statistics

Number of measurements over the years

Number of measurements per person

Distribution of lab values

Value range per person

LabWAS